| iPSC-Derived Noradrenergic Neurons | |
|---|---|
| Lineage | Stem Cell > iPSC > Noradrenergic |
| Markers | DBH, TH, PHOX2A |
| Brain Regions | In Vitro |
| Disease Relevance | Parkinson's Disease, Depression |
iPSC-derived noradrenergic neurons are specialized neurons generated from induced pluripotent stem cells (iPSCs) that exhibit the molecular and functional properties of endogenous locus coeruleus noradrenergic neurons. These cells provide a critical in vitro model for studying Parkinson's disease (PD), depression, and norepinephrine-related neurodegeneration[1].
Differentiation of iPSCs into noradrenergic neurons follows a protocol that recapitulates the development of the locus coeruleus:
iPSC-derived noradrenergic neurons express canonical markers:
| Marker | Function | Detection Method |
|---|---|---|
| TH | Rate-limiting enzyme in catecholamine synthesis | Immunohistochemistry |
| DBH | Dopamine β-hydroxylase | qPCR, Western blot |
| PNMT | Phenylethanolamine N-methyltransferase | Immunohistochemistry |
| PHOX2A/B | Transcription factors | RNA-seq |
| NET (SLC6A2) | Norepinephrine transporter | Functional assay |
Single-cell RNA sequencing shows that iPSC-derived noradrenergic neurons cluster with primary locus coeruleus neurons and express characteristic transcription factors including PHOX2A, PHOX2B, and FEV[3].
Mature iPSC-derived noradrenergic neurons exhibit:
iPSC-derived noradrenergic neurons from PD patients show:
Noradrenergic dysfunction is central to depression pathophysiology:
These neurons model:
| Property | iPSC-Derived | Primary Human LC |
|---|---|---|
| Availability | Unlimited | Very limited |
| Maturation | 6-8 weeks | N/A |
| Purity | 50-70% | Native |
| Functionality | Partial | Full |
The study of Ipsc Derived Noradrenergic Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Induced pluripotent stem cells: Disease modeling and drug discovery for neurodegenerative disorders (Neuron, 2023) ↩︎
Directed differentiation of human iPSCs into locus coeruleus noradrenergic neurons (Nature Neuroscience, 2022) ↩︎
Single-cell transcriptomics of human noradrenergic neurons reveals disease-state signatures (Cell Stem Cell, 2024) ↩︎
Noradrenergic dysfunction in Parkinson's disease iPSC models (Brain, 2023) ↩︎